Plasma phosphorylated tau 217 and phosphorylated tau 181 as biomarkers in Alzheimer’s disease and frontotemporal lobar degeneration: A retrospective diagnostic performance study
10.1016/s1474-4422(21)00214-3 · doi-reference
Targeting tau: Clinical trials and novel therapeutic approaches
10.1016/j.neulet.2020.134919 · doi-reference
Targeted degradation of aberrant tau in frontotemporal dementia patient-derived neuronal cell models
10.7554/elife.45457 · doi-reference
Ultrasound-mediated blood–brain barrier opening enhances delivery of therapeutically relevant formats of a tau-specific antibody
10.1038/s41598-019-45577-2 · doi-reference
Blood–brain barrier opening in Alzheimer’s disease using MR-guided focused ultrasound
10.1038/s41467-018-04529-6 · doi-reference
10.3389/fphar.2022.974666
10.3389/fphar.2022.974666 · doi-reference
Preliminary safety and tolerability of a novel subcutaneous intrathecal catheter system for repeated outpatient dosing of nusinersen to children and adults with spinal muscular atrophy
10.1097/bpo.0000000000001247 · doi-reference
10.3390/biomedicines13092167
10.3390/biomedicines13092167 · doi-reference
Delivery of nusinersen through an Ommaya reservoir in spinal muscular atrophy
10.1097/cnd.0000000000000333 · doi-reference
Nusinersen initiated in infants during the presymptomatic stage of spinal muscular atrophy: Interim efficacy and safety results from the phase 2 NURTURE study
10.1016/j.nmd.2019.09.007 · doi-reference
Design of a phase 2, randomized, double-blind, placebo-controlled, parallel-group study to assess the efficacy, safety, and tolerability of BIIB080 in subjects with mild cognitive impairment due to Alzheimer’s disease or mild Alzheimer’s disease dementia
10.1002/alz.077322 · doi-reference
Delivery of oligonucleotide-based therapeutics: Challenges and opportunities
10.15252/emmm.202013243 · doi-reference
Pre-mRNA splicing in disease and therapeutics
10.1038/nrg.2015.3 · doi-reference
The chemical evolution of oligonucleotide therapies of clinical utility
10.1038/nbt.3765 · doi-reference
Brain drug delivery: Overcoming the blood-brain barrier to treat tauopathies
10.2174/1381612826666200316130128 · doi-reference
Inhibitory RNA aptamers of tau oligomerization and their neuroprotective roles against proteotoxic stress
10.1021/acs.molpharmaceut.6b00165 · doi-reference
Functional selection of tau oligomerization-inhibiting aptamers
10.1002/anie.202402007 · doi-reference
10.3390/ph19010164
10.3390/ph19010164 · doi-reference
Structural basis for recognition of the RNA major groove in the tau exon 10 splicing regulatory element by aminoglycoside antibiotics
10.1093/nar/28.3.710 · doi-reference
10.3389/fmolb.2025.1750807
10.3389/fmolb.2025.1750807 · doi-reference
10.1038/s41551-026-01747-y
10.1038/s41551-026-01747-y · doi-reference
Efficient prime editing in mouse brain, liver and heart with dual AAVs
10.1038/s41587-023-01758-z · doi-reference
Prime editing corrects the dilated cardiomyopathy causing RBM20-P633L-mutation in human cardiomyocytes
10.1016/j.omtn.2025.102734 · doi-reference
Systematic optimization of prime editing for the efficient functional correction of CFTR F508del in human airway epithelial cells
10.1038/s41551-024-01233-3 · doi-reference
Programmable editing of a target base in genomic DNA without double-stranded DNA cleavage
10.1038/nature17946 · doi-reference
10.3389/fbioe.2022.951384
10.3389/fbioe.2022.951384 · doi-reference
Trans-splicing correction of tau isoform imbalance in a mouse model of tau mis-splicing
10.1093/hmg/ddt108 · doi-reference
Correction of tau mis-splicing caused by FTDP-17 MAPT mutations by spliceosome-mediated RNA trans-splicing
10.1093/hmg/ddp264 · doi-reference
Spliceosome-mediated RNA trans-splicing as a tool for gene therapy
10.1038/6986 · doi-reference
Reprogramming of tau alternative splicing by spliceosome-mediated RNA trans-splicing: Implications for tauopathies
10.1073/pnas.0503150102 · doi-reference
Development of an oral treatment that rescues gait ataxia and retinal degeneration in a phenotypic mouse model of familial dysautonomia
10.1016/j.ajhg.2023.01.019 · doi-reference
Small molecule modulators of pre-mRNA splicing in cancer therapy
10.1016/j.molmed.2015.11.005 · doi-reference
Small molecule targeting of RNA structures in neurological disorders
10.1111/nyas.14051 · doi-reference
A deep learning approach to identify gene targets of a therapeutic for human splicing disorders
10.1038/s41467-021-23663-2 · doi-reference
SMN2 splice modulators enhance U1-pre-mRNA association and rescue SMA mice
10.1038/nchembio.1837 · doi-reference
Discovery of risdiplam, a selective survival of motor neuron-2 (SMN2) gene splicing modifier for the treatment of spinal muscular atrophy (SMA)
10.1021/acs.jmedchem.8b00741 · doi-reference
Design of an orally bioavailable small molecule that modulates the microtubule-associated protein tau’s pre-mRNA splicing
10.1021/acschembio.5c00260 · doi-reference
10.3390/molecules26082263
10.3390/molecules26082263 · doi-reference
Design, optimization, and study of small molecules that target tau pre-mRNA and affect splicing
10.1021/jacs.0c00768 · doi-reference
Bottom-up design of small molecules that stimulate exon 10 skipping in mutant MAPT pre-mRNA
10.1002/cbic.201402069 · doi-reference
